Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 9/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.55 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5235432 | 0.82 | CDK5 (0.61) | CDK5CDK5R1 | |
| SCHEMBL14608812 | 0.74 | CDK5 (0.60) | CDK5CDK5R1 | |
| SCHEMBL5238812 | 0.72 | CDK5 (1.00) | CDK5CDK5R1 | |
| SCHEMBL5233908 | 0.71 | ROCK1 (0.42) | ROCK1ROCK2MTORKDM4ECHRM4 | |
| SCHEMBL5235092 | 0.66 | CDK5 (1.00) | CDK5CDK5R1 | |
| SCHEMBL5265822 | 0.63 | CDK5 (0.54) | CDK5CDK5R1 | |
| SCHEMBL1601864 | 0.63 | KIT (0.50) | ROCK1ROCK2MTORKDM4E | |
| SCHEMBL30726450 | 0.62 | DRD1 (0.56) | KDM4EMAOB | |
| SCHEMBL1100987 | 0.61 | PIK3CD (0.53) | KDM4E | |
| SCHEMBL5234594 | 0.61 | CDK5 (1.00) | CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1507776-B1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7119111-B2 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | AMGEN INC. | 2003-12-11 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229068-A1 | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use | CASP3, BAX, BAD | CDK5 88/4885CDK5R1 252/4885ROCK1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.